Chris Ryan joined OncLive in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com
Iopofosine I-131 Under Further Investigation in CLOVER WaM Trial in Waldenström Macroglobulinemia
June 23rd 2022Sikander Ailawadhi, MD, discusses early efficacy observed with iopofosine I-131, the rationale of investigating the agent in the CLOVER WaM trial in patients with Waldenström macroglobulinemia, and how the radiotherapeutic could affect the treatment paradigm.
Read More
CHMP Recommends Melphalan Flufenamide for Triple-Class Refractory Multiple Myeloma
June 23rd 2022The European Medicines Agency's Committee for Medicinal Products for Human Use has unanimously recommended full marketing authorization approval of melphalan flufenamide for patients with triple-class refractory multiple myeloma.
Read More
Nemtabrutinib Generates Responses, Displays Manageable Safety in CLL/SLL
June 20th 2022Nemtabrutinib, a potent, non-covalent BTK inhibitor, continued to demonstrate antitumor activity with an acceptable safety profile in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.
Read More
Cilta-cel Produces Durable Responses in Relapsed/Refractory Multiple Myeloma
June 20th 2022A single infusion of the CAR T-cell therapy ciltacabtagene autoleucel produced deep and durable responses in patients with relapsed/refractory multiple myeloma with a manageable toxicity profile, according to long-term follow-up data of the phase 1b/2 CARTITUDE-1 trial.
Read More
Repotrectinib Receives Breakthrough Therapy Designations in China for ROS1+ NSCLC
June 17th 2022The China National Medical Products Administration’s Center for Drug Evaluation granted 2 breakthrough therapy designations to repotrectinib for the treatment of patients with ROS1-positive metastatic non–small cell lung cancer.
Read More
Using NGS to Detect NRG1 Fusions Could Guide Treatment in NSCLC and Other Solid Tumors
June 14th 2022Next-generation panel sequencing and a unique algorithm demonstrated the advantage of detecting NRG1 fusions and providing structure information of partners, which could ultimately guide more precise therapeutic options, according to data from a study done in Chinese patients with solid tumors.
Read More
Ropeginterferon Alfa-2b Demonstrates Long-Term QOL Improvements in Polycythemia Vera
June 13th 2022Treatment with ropeginterferon alfa-2b-njft induced low symptom burden and low phlebotomy requirement compared with best available treatment in patients with polycythemia vera, according to long-term data from the phase 3 PROUD-PV and CONTINUATION-PV trials.
Read More
CAR T-Cell Therapy ARI0002H Elicits Encouraging Responses in Relapsed/Refractory Multiple Myeloma
June 11th 2022ARI0002H, a BCMA-directed CAR T-cell therapy, achieved promising response rates in patients with relapsed/refractory multiple myeloma, according to findings from a phase 1/2 trial.
Read More
NPM1 Mutations, MRD Responses Linked to Long-Term Survival Benefits With Azacitidine in AML
June 10th 2022Oral azacitidine was associated with improved long-term survival in patients with acute myeloid leukemia who harbored NPM1 mutations, had intermediate-risk cytogenetics at diagnosis, had a longer treatment duration, or a minimal residual disease response during treatment.
Read More
Frontline BTK Inhibitors Improve OS in Real-World Patients with MCL
June 2nd 2022The use of BTK inhibitors as a frontline treatment improved overall survival vs their deployment in subsequent lines of therapy in patients with mantle cell lymphoma, according to a real-world study (IRB-300004501) published in Blood Advances.
Read More
Fixed-Duration Ibrutinib/Venetoclax Significantly Prolongs PFS Over SOC in CLL and Comorbidities
June 2nd 2022The fixed-duration combination of ibrutinib and venetoclax produced deep responses and improved progression-free survival vs chlorambucil plus obinutuzumab when used in previously untreated patients with chronic lymphocytic leukemia who were older and/or who had comorbidities, according to findings from the phase 3 GLOW trial.
Read More
Zanubrutinib Approved in Uruguay for MCL, MZL, and Waldenström Macroglobulinemia
May 27th 2022The BTK inhibitor zanubrutinib has been approved in Uruguay for the treatment of adult patients with previously treated mantle cell lymphoma, relapsed or refractory marginal zone lymphoma, and Waldenström macroglobulinemia.
Read More
Nivolumab Plus Axitinib Generates Promising Responses in Untreated Advanced RCC
May 24th 2022The combination of nivolumab and axitinib achieved meaningful responses in treatment-naïve advanced renal cell carcinoma, according to results from a phase 1/2 trial (NCT03172754) presented at the 2022 Genitourinary Cancers Symposium.
Read More
European Approval Sought for Adagrasib in Previously Treated KRAS G12C–Mutated NSCLC
May 20th 2022A marketing authorization application has been submitted to the European Medicines Agency seeking the approval of adagrasib for therapeutic use in previously treated patients with non–small cell lung cancer harboring a KRAS G12C mutation.
Read More